Brief Introduction

BioPerfectus is one of the leading molecular diagnostic solution manufacturers in global in-vitro diagnostics market since 2010. With headquarter located in Taizhou, branch offices sited in Taizhou, Haikou, Yinchuan, Shanghai, Xian and Beijing, Bioperfectus is pioneering in molecular diagnostics market with our products ranging from real time PCR kits, nucleic acid extraction systems, rapid tests and automation laboratory devices etc... By the end of 2020, the company has obtained 71 domestic medical device registration/filing certificates, 36 domestic authorized patents and 16 software Copyrights. It strives to integrate quality, efficiency, fairness and impartiality into its core culture, and provide the best products and services.

Company Overview

Full name Jiangsu Bioperfectus Technologies Co., Ltd.
Abbreviations sssw
Code 688399
Founded Apr 12th, 2010
Listing Dec 5th, 2019
Domicile Taizhou, Jiangsu, China
STAR Theme Biomedicine
CSRC Sector Manufacturing
Has weighted voting rights structure? No



  2020 2019 2018
Earnings Per Share 13.98 1.85 1.45
R&D expenditure as a % of operating revenue 4.14% 13.35% 11.44%
Operating Revenue 1,739,680,701.97 288,794,709.93 230,700,330.36
Net Income 819,567,339.93 83,756,179.76 63,824,573.32

Income Statement (Unit: RMB mn)

  2020 2019 2018
Operating Revenue 1,739.68 288.79 230.70
Operating Costs 830.25 200.36 169.08
Operating Income 963.01 95.04 73.29
Pretax Income 960.99 94.70 72.97
Income Tax 141.42 10.94 9.15
Net Income 819.57 83.76 63.82

Balance Sheet(Unit: RMB mn)

  2020 2019 2018
Current Assets-Total 1,779.86 890.45 253.64
Non-current Assets-Total 497.82 263.91 141.92
Total Assets 2,277.67 1,154.36 395.56
Current Liabilities-Total 522.45 94.23 55.40
Non-current Liabilities-Total 90.73 39.34 16.06
Total Liabilities 613.18 133.57 71.46
Stockholder's Equity
Share Capital 863.30 863.30 250.37
Retained Profits 801.19 157.49 73.73
Total Owners' Equity 1,664.50 1,020.79 324.10

Cash Flow Statement (Unit: RMB mn)

  2020 2019 2018
Net Cash Flows-Operating 935.88 106.72 85.82
Net Cash Flows-Investing -259.60 -654.42 -75.41
Net Cash Flows-Financing -125.89 612.93 -

Top 10 Shareholders

Name No. of Shares Held (mn) % of Shares Held
绍兴闰康生物医药股权投资合伙企业(有限合伙) 15.60 26.61%
Guoqiang Wang 4.95 8.44%
Xu Zhang 2.64 4.51%
The CID Group 2.24 3.82%
北京苇渡资本管理有限公司-宁波苇渡一期医疗创业投资合伙企业(有限合伙) 1.87 3.19%
Zhonghua Liu 1.45 2.48%
宁波独角兽创业投资合伙企业(有限合伙) 1.13 1.93%
泰州硕康企业管理咨询合伙企业(有限合伙) 1.08 1.84%
泰州硕源企业管理咨询合伙企业(有限合伙) 1.08 1.84%
Shanghai Tianyi Asset Management Co., Ltd 1.06 1.80%
As of 2021-03-31

Legal Statement

All information contained herein is provided by the underlying company itself and is for informational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. The Shanghai Stock Exchange does not guarantee its accuracy and reliability and shall under no circumstance be responsible or liable for any error or for any loss directly or indirectly arising from any inaccuracy or omission or from any decision, action or non-action based on or in reliance upon the information herein.

Users may view and download the information herein for personal and non-commercial use free of charge subject to the laws of the People's Republic of China and the Legal Statement. No part of the information herein may be copied, downloaded, stored in a retrieval system or transmitted in any form or by any means, rented, displayed, performed, reproduced, photocopied, altered, sold, broadcast, published or otherwise in whole or in part in any manner for commercial purposes, without the prior written consent of the Shanghai Stock Exchange.

Users are hereby reminded that the Legal Statement represents your legally binding agreement with the Shanghai Stock Exchange. By accessing or using this website, you are also signifying your agreement with and acceptance of all the contents in the Legal Statement. The Shanghai Stock Exchange reserves the right to amend and interpret the Legal Statement.